Digitizing Healthcare – Embracing change. Creating opportunity.
Atif Elahi and Emily Wyatt
The future of healthcare is digital
For many industries, embracing digitization has become a matter of survival. Healthcare has always had a reputation of being resistant to change, but consumer demand and a rapidly evolving technology-driven world have led the digitization of healthcare to move at a frantic pace.
In comparison with other industries, healthcare has been slow to take advantage of the digital revolution. Traditionally healthcare has always been a difficult industry in which to innovate; it is highly regulated, expensive, complex and risk averse. However, rising drug development costs, increased patient expectations, and a growing dependence on health resources, place the industry under increasing pressure to move with the times. Many organizations with an interest in health, including the pharmaceutical industry, medical technology companies, health insurers, and payers are focusing on the digital world. However, the strongest digital health innovators are now coming in from outside the industry.
How tech companies are driving digital transformation
Healthcare represents an incredibly lucrative opportunity for traditional technology companies. The tech giants – Alphabet (the parent company of Google), Amazon, Apple, Microsoft and IBM – are taking the lead and heavily investing their time, resource and talent into healthcare.
Each of the major tech companies are using their core business strengths to create digital health initiatives across a variety of platforms. These are being implemented at every touchpoint of the patient/health professional journey ranging from data storage, artificial intelligence (AI), e-commerce, voice-enabled solutions, consumer apps and wearables. By developing tools that patients and health professionals embrace, and through collaborations with healthcare providers, the Big 5 are poised to reinvent the healthcare industry.
Atif Elahi, PhD
Atif is a Senior Manager based in London. Atif has 5+ years life sciences consulting experience, having led engagements for clients focused on corporate strategy, launch preparation and optimization, competitive strategy and product lifecycle management. He has strong analytical, client management and facilitation skills allowing him to lead clients, projects and teams.
Emily is a Senior Associate based in the London office. Since joining Deallus, Emily has lead research for top tier pharmaceutical clients supporting their global strategy to implement personalised healthcare initiatives across the value chain. She has also facilitated competitive simulation workshops looking at the impact of Tech disruption in healthcare.
As the impact of COVID-19 pandemic continues to expand globally, pharmaceutical and biotech players are beginning to feel the disruptive effects of the outbreak. New clinical trials will be significantly delayed as companies continue to face challenges arising from COVID-19, from potential patient quarantines, to site closures, travel limitations or interruptions to the supply chain for new investigational products.
Deallus is excited to announce that Jenny Cummins will be partnering with Deallus as a Strategic Advisor. Jenny’s experience in formulating strategic direction within and outside of pharmaceutical companies is something we are excited to add to our panel of strategic advisors. Our clients will benefit from her expertise in the healthcare sector as well as her impressive leadership, communication, and facilitation skills.
We are excited to announce that Gloria Kwon has joined our Deallus team as a Senior Principal based out of our Los Angeles office. Gloria comes to Deallus with significant experience in business strategy, product commercialization and operational excellence for pharmaceutical and biotechnology companies. Prior to joining Deallus, Gloria spent over 8 years at Navigant Consulting.
Deallus is pleased to announce that Peter Barschdorff is joining the organization as Vice President, leading its U.S. consulting business, with offices in Los Angeles and New York. Peter has held leadership positions in a number of management consulting organizations and has built innovative enterprise capabilities in commercial pharma.